Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Altastaph recommended to receive orphan medicinal product status in Europe

Sep. 27, 2005

Nanobodies may substitute monoclonal antibodies

Sep. 26, 2005

Cytheris initiates additional phase I/II trial with recombinant interleukin-7

Sep. 22, 2005

Marketing suspension of Hexavac recommended by the EMEA

Sep. 21, 2005

Novel immunomodulating agents revealed in patents

Sep. 19, 2005

Immunosuppressant S1P1 receptor agonists prepared and tested at Merck & Co.

Sep. 12, 2005

Mechanisms underlying SERP-1 mediated inhibition of monocytic adhesion and migration

Sep. 12, 2005

CYC-10268 targets macrophage survival in vitro

Sep. 9, 2005

Hemispherx reports preclinical studies on dsRNA

Sep. 8, 2005

Canadian phase II study for ragweed allergy vaccine

Sep. 8, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...